Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
41 results about "Oxidized ldl" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Oxidized LDL. Plasma levels of Ox-LDL are a sensitive biomarker of atherosclerosis. Elevated Ox-LDL is associated with accelerated atherogenesis, CAD, acute myocardial infarction, and stable and unstable angina.
Methods and reagents for non-invasive imaging of atherosclerotic plaque
The invention provides reagents and methods for their use in in vivo diagnosis of atherosclerosis. In particular, the invention provides monoclonal antibodies which bind oxidation specific epitopes in atherosclerotic plaque lesions, such as those which occur in oxidized LDL, in vivo with high binding specificity; i.e., at about 10 to 20 times the rate of binding of the antibodies to adjacent normal arterial tissue. When detectably labeled and administered according to the invention, the antibodies are clearly imaged when bound to atherosclerotic plaque using known imaging techniques and devices, such as a gamma camera. In addition, the invention provides a method for substantially reducing interference from background signal in the blood pool into which such agents are introduced for detection and quantification of atherosclerotic plaque burden in the cardiovascular tissue of a host.
Owner:RGT UNIV OF CALIFORNIA
Atherosclerosis vaccine
InactiveUS20040002111A1Peptide preparation methodsLipid/lipoprotein ingredientsAntigenComplementarity determining region
The present invention relates to an antigenic composition capable of eliciting antibodies by interacting with alphabeta chains of a T cell receptor (TcR), which composition is comprised of a peptide-aldehyde conjugate. The aldehyde portion may be a dialdehyde, such as malondialdehyde (MDA), or a monoaldehyde, such as 4-hydroxynonenal (4-HNE), while the peptide portion preferably comprises at least one lysine residue. The antigenic composition according to the invention is capable of recognizing and interacting with a TcR having a complementarity-determining region 3 (CDR3) of alpha10 and beta6 chains that comprises a cluster of charged and polar amino acids. The invention also relates to a method of producing a vaccine against atherosclerosis by screening of a library of candidate compounds for their ability to bind to a conjugate of oxidized LDL and a dialdehyde as well as to such a vaccine as such.
Owner:CARDIOVAX
Dairy cattle breeding for improved milk production traits in cattle
InactiveUS20070015164A1Highly desirable milk production traitIncreased milk fatSugar derivativesMicrobiological testing/measurementHeifer calfMilk cow's
Nucleic acid molecules comprising a SNP site selected from the group consisting of position 1296 of bovine uterine milk protein (UTMP) coding sequence (SEQ ID NO: 1), position 213 of bovine signal transducer and activator of transcription (STAT1) coding sequence (SEQ ID NO: 2), position 8514 of the osteopontin (OPN) gene (SEQ ID NO: 3), or position 1070 of a bovine lectin-like oxidized LDL receptor (OLR1) coding sequence (SEQ ID NO: 4), which SNP indicates a desirable milk production trait in a dairy cattle. Also disclosed are an array or a kit comprising the same, a method for detecting the SNPs, a method for progeny testing of cattle, and a method for selectively breeding of cattle.
Owner:WISCONSIN ALUMNI RES FOUND
Agents and Methods for Osteogenic Oxysterols Inhibition of Oxidative Stress on Osteogenic Cellular Differentiation
InactiveUS20090202660A1Eliminating and minimizing effectInhibition of osteogenic differentiationBiocideOrganic active ingredientsPurine-Xanthine OxidaseBone Marrow Stromal Cell
The present invention discloses oxygenic oxygenic oxysterols. Also disclosed, agents and methods for protecting, blocking or rescuing marrow stromal cells from the inhibitory effects of oxidative stress on their osteoblastic cellular differentiation. Exemplary agents include oxysterols, rhBMP2, alone or in combination which are demonstrated to specifically combat oxidative stress caused by inflammatory oxidized lipids, such as xanthine / xanthine oxidase and minimally oxidized LDL. The synergistic effects of oxysterols and bone morphogenic proteins are disclosed.
Owner:RGT UNIV OF CALIFORNIA
Compounds having Anti-proliferative properties
InactiveUS20110003774A1Scavenger cell expression or oxidised LDL uptake may be reduced or restrainedBiocideOrganic active ingredientsSmooth muscleMonocyte
Owner:VITAL HEALTH SCIENCES PTY LTD
Activation of Human Antigen-Presenting Cells Through Dendritic Cell Lectin-Like Oxidized LDL Receptor-1 (LOX-1)
ActiveUS20080267984A1Highly predictive of therapeutic outcomeImprove protectionAntibacterial agentsSenses disorderAntigenBiological activation
The present invention includes compositions and methods for targeting the LOX-1 receptor on immune cells and uses for the anti-LOX-1 antibodies.
Owner:BAYLOR RES INST
Liposomally Encapsulated Reduced Glutathione, including with Other Pharmacologic Preparation, Capable of Administration as an Oral, Topical, Intraoral or Transmucosal, Prepartion, for Reversal and Prevention of Oxidation of Cholesterol and of Low Density Lipoprotein
The invention proposes the sure of reduced glutathione in a liposome (liposomal reduced glutathione) for the oral administration of a therapeutically effective amount to ameliorate the progression of vascular disease, including atherosclerosis, diabetes, hypertension, narrowing of arteries leading to decreased blood flow, ischemic events, and the formation of blood clots, abnormal platelet aggregation, and thrombotic events, by reducing the amount and effect of oxidized cholesterol, oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with statin drugs to improve the effect of lowering not only cholesterol but also the oxidized cholesterol as well as oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with CoQ10 as a therapy for vascular disease and management of side effects of statin therapy.
Owner:YOUR ENERGY SYST
Labeled ligands for lectin-like oxidized low-density lipoprotein receptor (LOX-1)
InactiveUS20050089471A1Ultrasonic/sonic/infrasonic diagnosticsGeneral/multifunctional contrast agentsCoronary artery diseaseImaging agent
Embodiments of the present invention relates to compounds labeled with imaging agents that also are capable of binding lectin-like oxidized low-density lipoprotein (LOX-1). The labeled compounds are useful for the diagnosis and monitoring of diseases in which inflammation plays a role, such as various cardiovascular diseases including but not limited to atherosclerosis, vulnerable plaque, and coronary artery disease, as well as rheumatoid arthritis.
Owner:GENERAL ELECTRIC CO
Saliva immunoassay for detection of antibodies for cardiovascular disease
InactiveUS20060094073A1OptimizationImprove the level ofDisease diagnosisBiological testingImmune complex depositionAntibody level
A method for diagnosing the likelihood and severity of cardiovascular disease in a patient is disclosed. The method determines the levels of antibodies against autoantigens, including myosin, oxidized LDL, β-2-glycoprotein, heat shock protein-60, platelet glycoprotein, and immune complexes. It then compares the results to normal levels to determine the likelihood and severity of cardiovascular disease.
Owner:IMMUNOSCI LAB
Saliva immunoassay for detection of antibodies for cardiovascular disease
A method for diagnosing the likelihood and severity of cardiovascular disease in a patient is disclosed. The method determines the levels of antibodies against autoantigens, including myosin, oxidized LDL, β-2-glycoprotein, heat shock protein-60, platelet glycoprotein, and immune complexes. It then compares the results to normal levels to determine the likelihood and severity of cardiovascular disease.
Owner:IMMUNOSCI LAB
Targeting metastasis stem cells through a fatty acid receptor (CD36)
ActiveUS20190106503A1Diminish of metastasis growthPromote growthCompound screeningApoptosis detectionLipid formationLymphatic Spread
Metastasis stem cells are targeted through a fatty acid receptor. Blockers or inhibitors of CD36 activity or expression are for the treatment of oral squamous cell cancer (OSCC), particularly for the treatment of generated metastases and for diminishing generation from primary tumors. Apart from shRNAs, anti-CD36 antibodies are provided as blockers or inhibitors, especially those that block the binding of CD36 to oxidized LDL and fatty acids and their incorporation into cells, because the promotion of their transport is indicated as the mechanism by which CD36 promote metastases dissemination and growth. A method identifies candidates to anticancer agents, particularly for OSCC metastasis, among those that promote in CD36+ cells, in vivo or in vitro, effects associated to CD36 depletion or blocking such as decrease of growth accumulation of lipid droplets and decrease of size in the case of metastases.
Owner:FUNDACIO INST DE RECERCA BIOMEDICA (IRB BARCELONA) +1
Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized LDL receptor-1 (LOX-1)
ActiveUS8481314B2Enhance cellular immune responseIncrease productionAntibacterial agentsSenses disorderAntigenBiological activation
The present invention includes compositions and methods for targeting the LOX-1 receptor on immune cells and uses for the anti-LOX-1 antibodies.
Owner:BAYLOR RES INST
Monoclonal antibody against slightly oxidized low-density lipoprotein and hybridoma for producing the same
ActiveUS20130253174A1Simple methodGood effectImmunoglobulins against animals/humansBiological testingMonoclonal antibodyLow-density lipoprotein
Owner:HOKKAIDO UNIVERSITY
Heat shock protein as a targeting agent for endothelium-specific in vivo transduction
InactiveUS7575738B2Sufficient specificityIn-vivo radioactive preparationsIsotope introduction to peptides/proteinsHeat shockImaging agent
The present invention relates to the use of Heat Shock Proteins and fragments thereof as targeting ligand. The Heat Shock Protein may be labeled with imaging agents that are capable of binding lectin-like oxidized low-density lipoprotein (LOX-1) or may be attached to a therapeutic agent. The sequences are useful for the diagnosis and monitoring of diseases as well as means for internalizing signaling moieties and therapeutics.
Owner:GENERAL ELECTRIC CO
Method for the simultaneous and direct determination of serum cholesterol in high and low density lipoproteins using infrared spectroscopy
InactiveUS7022527B2Radiation pyrometryAnalysis by material excitationInfraredVery low-density lipoprotein
A method of simultaneously determining the concentrations of cardiovascular risk markers selected from the group consisting of High Density Lipoprotein cholesterol (HDL-C), Low Density Lipoprotein cholesterol (LDL-C), total cholesterol, triglycerides and oxidized LDL using infra-red and / or near infrared light is described.
Owner:NAT RES COUNCIL OF CANADA
Heat shock protein as a targeting agent for endothelium-specific in vivo transduction
InactiveUS20060034761A1Readily apparentIn-vivo radioactive preparationsIsotope introduction to peptides/proteinsHeat shockImaging agent
The present invention relates to the use of Heat Shock Proteins and fragments thereof as targeting ligand. The Heat Shock Protein may be labeled with imaging agents that are capable of binding lectin-like oxidized low-density lipoprotein (LOX-1) or may be attached to a therapeutic agent. The sequences are useful for the diagnosis and monitoring of diseases as well as means for internalizing signaling moieties and therapeutics.
Method of therapy and diagnosis of atherosclerosis
InactiveUS20120252867A1Promote migrationIncreased proliferationOrganic active ingredientsSugar derivativesBiological bodyPlasma samples
There is provided a method of therapy of atherosclerosis, by providing microRNA let-7g, an analogue thereof or modified let-7g to organisms to inhibit the expression of lectin-like oxidized low density lipoprotein receptor-1 (LOX-1), and the binding of LOX-1 and oxidized low-density lipoprotein (oxLDL), so as to block the pathogenesis of atherosclerosis. Also, a method of diagnosis of atherosclerosis comprises determining the levels of microRNA let-7g in serum or plasma samples of organisms, in which the levels of microRNA let-7g is estimated in individuals with atherosclerosis as compared to individuals without atherosclerosis.
Owner:KAOHSIUNG MEDICAL UNIVERSITY
Antibody against oxidized LDL/beta2GPI complex and use of the same
From antibodies that can be used to immunostain atherosclerotic tissue sections, the present inventors selected antibodies applicable to in vivo imaging, and analyzed their specificities. The result showed that fluorescently labeled anti-oxidized LDL / β2GPI complex antibodies that are specific to a particular epitope were effective for imaging.
Owner:UNIV OKAYAMA
Biotinylated and oxidized ldl receptor and advanced glycation end product receptor produced using genetically engineered silkworm
ActiveUS20170354129A1Good effectImprove efficiencyImmunoglobulin superfamilyPolypeptide with affinity tagADAMTS ProteinsBiotin
The present invention pertains to a silkworm-type biotinylated CTLD14 or sRAGE and a method for manufacturing the same. One embodiment of the present invention provides a method for manufacturing biotinylated proteins, wherein the method includes A) a step for inserting a nucleic acid molecule for coding biotin ligase and protein in a coexpressable manner into a silkworm or a living organism that imparts sugar chains that are the same as the sugar chains of the silkworm, B) a step for causing the biotin ligase and protein to be expressed by disposing the silkworm or the living organism that imparts sugar chains that are the same as the sugar chains of the silkworm to conditions with which the nucleic acid molecule will carry out expression, and C) a step for administering biotin to the living organism and obtaining the biotinylated protein.
Owner:NAT AGRI & FOOD RES ORG
Antibody against oxidized ldl/ß2gpi complex and use of the same
ActiveUS20110182816A1Reduce eliminateHybrid immunoglobulinsImmunoglobulins against animals/humansEpitopeFluorescence
From antibodies that can be used to immunostain atherosclerotic tissue sections, the present inventors selected antibodies applicable to in vivo imaging, and analyzed their specificities. The result showed that fluorescently labeled anti-oxidized LDL / β2GPI complex antibodies that are specific to a particular epitope were effective for imaging.
Owner:UNIV OKAYAMA
Treatment of atherosclerosis
InactiveUS20080025970A1Inhibit bindingOrganic active ingredientsBiocideDiseaseOxidised low density lipoprotein
Inhibitors of the adhesion of monocytes to oxidised low density lipoprotein or other lipid raft ligand for the therapy or prophylaxis of a condition involving monocyte adhesion to oxidised LDL or other lipid raft ligand, such as atherosclerosis, rheumatoid arthritis, multiple sclerosis or glomerulonephritis. An assay for identifying such inhibitors.
Owner:POSTON ROBIN N
Monoclonal antibody against oxidized low-density lipoprotein
ActiveUS8729240B2Simple methodGood effectImmunoglobulins against animals/humansBiological testingMonoclonal antibodyOxidized low density lipoprotein
Provided is a monoclonal antibody against slightly oxidized LDL, which can play a role as an important tool in the research and development of oxidized LDL. Also provided are a kit for the simple detection of slightly oxidized LDL and a method for the simple detection of slightly oxidized LDL from the biological sample of a subject to be tested which use the monoclonal antibody. By means of ELISA (Enzyme-Linked Immunosorbent Assay) using the monoclonal antibody as the solid phase antibody and an anti-apolipoprotein B antibody as the detection antibody, the degree of reaction between a severely oxidized low-density lipoprotein and the monoclonal antibody is low in comparison to the degree of reaction between a slightly oxidized low-density lipoprotein and the monoclonal antibody, and the monoclonal antibody specifically reacts with an oxidized low-density lipoprotein.
Owner:HOKKAIDO UNIVERSITY
Antibodies to oxidized ldl
InactiveUS20140154705A1Obtain goodBioreactor/fermenter combinationsBiological substance pretreatmentsEpitopeBiomolecular complex
A method is described for obtaining antibodies binding specifically to an epitope resulting from in vivo modification of a biomolecule or biomolecular complex, where the in vivo modification results from expression of a transgene in an animal. An example of such a biomolecule or biomolecular complex is LDL and an example of such a transgene is human myeloperoxidase. Resulting antibodies and methods of using the antibodies are also described.
Owner:XEN BIOFLUIDX
Anticholesterol immunoglobulin to treat lipid raft diseases
Immunoreactive compositions and methods for immunizing animal, including, humans, cows, and fowl, against cholesterol and cholesterol derivatives, including cholesterol oxides, and their use in methods for reducing and preventing lipid raft-based diseases, including, but not limited to HIV-1, SARS, prion formation in Creutzfeldt-Jakob disease, and neutralizing oxidized modified lipoproteins, specifically, oxidized-LDL, oxidized-VLDL / IDL, and oxidized-chylomicrons, which contribute to the formation of fatty streaks and atherosclerotic plaques, are described.
Owner:ORIGO FOODS
Oxidized ldl specific antibody-fusion and conjugated proteins
InactiveUS20110182851A1Peptide/protein ingredientsImmunoglobulins against animals/humansSpecific iggConjugated protein
The present invention relates to complete oxidized LDL specific IgG fused or conjugated with at least one of the proteins of the group IL-10, TIMPs, and TGFβs to be used in a medicine, the use thereof for treatment of atherosclerosis and prevention of clinical events in patients with atherosclerosis, pharmaceutical compositions containing the same, as well as method for treatment of atherosclerosis and prevention of clinical events in patients with atherosclerosis.
Owner:FORSKARPATENT I SYD AB
Portable, rapid, and inexpensive diagnostic tests for cardiac disease risk
InactiveUS9885663B2Material analysis by observing effect on chemical indicatorBiological testingDisease riskRapid screening test
Cardiac disease is the world's leading cause of death. Cardiac Disease's pathogenesis is largely attributed to cholesterol, predominantly carried by low-density lipoproteins (LDL). However, recent research has found that oxidized-LDL is significantly more potent in the initiation and development of atherosclerosis. Tests for both cholesterol and ox-LDL tests are lab-based and expensive. With every third American at risk for Cardiac Disease, this invention discloses an on-site, ultra-low cost, rapid diagnostic test. The diagnostic test disclosed will enable a holistic assessment of Cardiac Disease risk. Furthermore, portability and ultra low-cost of the test put vital health data in the hands of patients and doctors. Additionally, the inkjet printing system disclosed can be used to mass produce the test strips on demand.
Owner:SUMATHIPALA ADRIEL
Control of gene induced by oxidated lipids in human artery wall cells
InactiveUS20050187141A1Easy to addImprove stabilityCompound screeningApoptosis detectionLipid formationMonocyte chemotaxis
This invention provides novel methods of inhibiting one or more symptoms of atherosclerosis. Also provided are assays for compounds that will inhibit the progression and / or ameliorate one or more symptoms of atherosclerosis. The methods and assays are based, in part, on the discovery that oxidized LDL or components thereof induce strong upregulation of MAP kinase phosphatase-1 which, in turn, is associated with an “inflammatory response” characteristic of atherosclerotic plaque formation. Inhibition of MKP-1 inhibits one or more symptoms of this response, e.g. monocyte adhesion, monocyte chemotaxis, differentiation into macrophages, etc. Inhibition of MKP-1 thus provides an effective method of inhibiting symptoms of atherosclerosis.
Owner:RGT UNIV OF CALIFORNIA
Portable, Rapid, and Inexpensive Diagnostic Tests for Cardiac Disease Risk
InactiveUS20170115228A1Liquid surface applicatorsMaterial analysis by observing effect on chemical indicatorDisease riskRapid screening test
Cardiac disease is the world's leading cause of death. Cardiac Disease's pathogenesis is largely attributed to cholesterol, predominantly carried by low-density lipoproteins (LDL). However, recent research has found that oxidized-LDL is significantly more potent in the initiation and development of atherosclerosis. Tests for both cholesterol and ox-LDL tests are lab-based and expensive. With every third American at risk for Cardiac Disease, this invention discloses an on-site, ultra-low cost, rapid diagnostic test. The diagnostic test disclosed will enable a holistic assessment of Cardiac Disease risk. Furthermore, portability and ultra low-cost of the test put vital health data in the hands of patients and doctors. Additionally, the inkjet printing system disclosed can be used to mass produce the test strips on demand.
Owner:SUMATHIPALA ADRIEL
Human monoclonal antibody having fat-reducing effect
A purified polypeptide having an amino acid sequence that is substantial identical with the amino acid sequence of SEQ ID NO:1, SEQ ID NO:3, or both, in which the polypeptide binds low density lipoproteins (LDL) or oxidized LDL (oxLDL), or both, and particularly binds well to LDL cholesterol and oxidized LDL cholesterol. The polypeptide may be used in combination with conventional adjuvants or carrier substances for producing a drug having a fat-reducing effect and for producing drugs for aiding in the treatment of renal diseases.
Owner:VOLLMERS HEINZ
Agent for preventing arteriosclerosis
InactiveUS20110009616A1Inhibit the oxidized LDL uptakeMetabolism disorderFunctional group formation/introductionVascular endotheliumAntagonism
The invention provides antiarterioscierosis agents containing as the active ingredient porphyrin derivatives or ester derivatives thereof as represented by the general formula (1) or (2); and foods or pharmaceutical compositions containing the agents. The porphyrin derivatives and the ester derivatives thereof exhibit an effect of inhibiting the bonding of oxidized LDL to LOX-1 expressed in vascular endothelial cells, macrophage an so on and an antagonistic effect of inhibiting the incorporation of oxidized LDL into cells through LOX-1, and are highly safe. [Chemical formula 1] (wherein R1 and R2 are each a hydrocarbon group having 1 to 4 carbon atoms or the like; and R3 to R8 are each a hydrocarbon group having 1 to 2 carbon atoms, formyl, or the like) [Chemical formula 2] (wherein R1 and R2 are each a hydrocarbon group having 1 to 4 carbon atoms or the like; and R3 to R8 are each a hydrocarbon group having 1 to 2 carbon atoms, formyl, or the like)
Owner:UHA MIKAKUTO CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com